TON - March 2017, Vol 10, No 2

Survivors of lower gastrointestinal cancers can successfully use Internet-based patient-reported outcomes tools to report late- and long-term effects of their cancer.
As a result of differences in biology, access to care, and psychosocial and socioeconomic circumstances, adolescent and young adult (AYA) patients with cancer face distinct challenges compared with their adult counterparts.
With an estimated 15.5 million cancer survivors living in the United States, there is an increased recognition of the need for continuing education of healthcare providers focused on this growing population.
Toxicities related to immunotherapies approved for the treatment of patients with non–small-cell lung cancer (NSCLC) are uncommon but can be life-threatening.
Endocrine therapy is known to reduce breast cancer risk by 30% when used as primary prevention in women at risk for the disease, and the reduction lasts for at least 20 years.
Breast cancer rates are increasing worldwide, paralleling increases in type 2 diabetes, obesity, and metabolic syndrome (MetS).
Breast density, which can affect the visualization of mammography, is one of the strongest and most consistent risk factors for breast cancer.
Occupational factors such as shift work disrupt circadian rhythm and can increase breast cancer risk, and the International Agency for Research on Cancer has classified shift work as a possible carcinogen.
The endocrine therapy landscape has evolved from tamoxifen and aromatase inhibitors to CDK4/6 inhibitors and mTOR inhibitors.
By improving chemotherapy-induced peripheral neuropathy (CIPN), administration of duloxetine may enable patients with advanced pancreatic cancer to continue their treatment regimen of gemcitabine plus nab-paclitaxel.
Page 2 of 3
Results 11 - 20 of 22